Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.
Tan
A C
AC
Brouwer
J T
JT
Glue
P
P
van Leusen
R
R
Kauffmann
R H
RH
Schalm
S W
SW
de Vries
R A
RA
Vroom
B
B
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin